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Chapel Hill, North CarolinaABSTRACT This article introduces a new functional imaging paradigm that uses optical coherence tomography (OCT) to
detect rehydrated, lyophilized platelets (RL platelets) that are in the preclinical trial stage and contain superparamagnetic iron
oxides (SPIOs) approved by the U.S. Food and Drug Administration. Platelets are highly functional blood cells that detect
and adhere to sites of vascular endothelial damage by forming primary hemostatic plugs. By applying magnetic gradient forces,
induced nanoscale displacements (magnetomotion) of the SPIO-RL platelets are detected as optical phase shifts in OCT. In this
article, we characterize the iron content and magnetic properties of SPIO-RL platelets, construct a model to predict their mag-
netomotion in a tissue medium, and demonstrate OCT imaging in tissue phantoms and ex vivo pig arteries. Tissue phantoms
containing SPIO-RL platelets exhibited >3 dB contrast/noise ratio at R1.5  109 platelets/cm3. OCT imaging was performed
on ex vivo porcine arteries after infusion of SPIO-RL platelets, and specific contrast was obtained on an artery that was
surface-damaged (P < 106). This may enable new technologies for in vivo monitoring of the adherence of SPIO-RL platelets
to sites of bleeding and vascular damage, which is broadly applicable for assessing trauma and cardiovascular diseases.INTRODUCTIONThe ability to contrast a specific disease process in a whole
organ or functional state of individual cells has become
a major emphasis of biomedical imaging technology devel-
opment (1). Cells are desirable targeting vehicles because
they can easily be cultured or harvested in large quantities
and naturally possess functional properties that man-made
agents can only approximate. Dynamic information can be
gained about the health or activity status of cells by means
of noninvasive imaging of cells labeled with contrast agents.
Recent advancements in cell-based imaging include
labeling immune cells to detect and enhance inflammatory
activity (2) and labeling stem cells to analyze tissue regen-
eration processes (3,4).
Platelets are particularly attractive as imaging vehicles,
because they adhere to sites of endothelial disruption from
a wide variety of pathological processes, are easily
harvested from donor blood, and readily take up contrast
agents through several mechanisms, including those in-
volved with innate immunity. Their pathophysiological
function is to detect and adhere to sites of vascular damage
for the formation of primary hemostatic plugs, and then to
amplify coagulation reactions to limit hemorrhage (5).
Disruption of vascular endothelium and frank vascular
breach can result from a wide variety of pathological
processes, including mechanical damage in trauma as well
as acute and chronic inflammation (6). The platelet is there-
fore a logical ‘‘plateform’’ for localizing imaging contrastSubmitted May 5, 2010, and accepted for publication August 5, 2010.
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0006-3495/10/10/2374/10 $2.00agents and therapeutics to vascular sites where inflamma-
tory processes perturb endothelial structure.
Rehydrated, lyophilized (RL) platelets (Stasix, Entegrion,
Research Triangle Park, NC), employed in this study, are an
infusion agent in preclinical trials for treating platelet-
responsive bleeding. RL platelets are prepared from fresh
human apheresis platelets by paraformaldehyde stabiliza-
tion, and provide a solution to the logistical difficulties of
platelet storage and harvesting (7). RL platelets have been
shown to avidly adhere to wound sites (7) and display a
broad-based functionality as a hemostatic agent in rabbit
(8), canine (9), and porcine (10) bleeding models. RL plate-
lets are an activatable hemostatic agent (11) that is removed
from the free circulation within minutes by the reticuloen-
dothelial system if not localized to sites of vascular injury
(12). In this work, superparamagnetic iron oxides (SPIOs)
comprised of MRI liver contrast agents (Feridex I.V.,
Advanced Magnetics, Lexington, MA) approved by the
U.S. Food and Drug Administration are incorporated into
platelets before paraformaldehyde stabilization. As we
demonstrate here, the resulting SPIO-RL platelets maintain
some hemostatic properties, while the SPIOs provide
a magnetic handle by which to contrast the RL platelets.
Optical coherence tomography (OCT) is a biological
imaging modality that provides noninvasive imaging on
a scale similar to that of histology (i.e., at the cellular level),
with millimeter-range imaging depth and micrometer-range
resolution (13). It has been widely adapted clinically for
ophthalmology (14), and increasingly applications are being
developed for imaging of the coronary artery (15), skin (16),
and upper airway (17), among other areas of interest (18).doi: 10.1016/j.bpj.2010.08.007
OCT of Magnetic Platelets 2375Magnetomotive OCT (MMOCT) is an emerging technique
for contrasting magnetic agents that exhibit a high magnetic
susceptibility against a tissue background, by magnetically
inducing nanoscale motions at a specific modulation
frequency during acquisition of an OCT image (19,20).
SPIOs are therefore excellent MMOCT contrast agents,
because they exhibit magnetic susceptibilities that are
~105 times greater than that of human tissue, including
red blood cells (21). The low modulation frequencies
employed in MMOCT (1–1000 Hz) avoid heating due to
magnetic fluid hyperthermia that typically occurs above
100 kHz (22). MMOCT has recently been applied to track
SPIOs labeled with HER2neu antibodies targeting a breast
cancer animal model in vivo (23).
In this article, we characterize the efficacy with which
MMOCT can be used to contrast SPIO-RL platelets. Exper-
iments are performed in tissue phantoms and porcine
arteries using SPIO-RL platelets at concentrations expected
to be similar to those in a typical in vivo infusion application
for targeting sites of vascular damage. Characterization of
the SPIO-RL platelet magnetic and contrast properties
provide insight into the strengths and limitations of this
technique. Because platelet-activating events are ubiquitous
in many disease processes, the ability to study the highly
dynamical function of platelets in flowing blood may
provide fundamental knowledge about hemostasis arising
from trauma and thrombosis, as well as vascular damage
arising from cardiovascular disease and certain cancer ther-
apies. Specific applications enabled by this technology may
include intravascular OCT imaging for the assessment of
thrombosis, and external OCT imaging for monitoring the
efficacy of SPIO-RL platelets to detect bleeding during
treatment for burn trauma.MATERIALS AND METHODS
Preparation of SPIO-RL platelets
In this work, SPIOs consisted of an infusible magnetic resonance imaging
liver contrast agent known as Feridex (a ferumoxides injectable solution;
Advanced Magnetics), which is comprised of ~5-nm SPIO cores with
a dextran coating (24) and a reported iron content of 11.2 mg Fe/mL. SPIOs
were diluted 1/10 from infusion-grade stock, combinedwith apheresis plate-
lets at 1  109/cm3, and incubated overnight, which resulted in internaliza-
tion of the SPIOs. After SPIO internalization, the nanoparticle-loaded
platelets are separated from extracellular SPIO with size-exclusion chroma-
tography and then stabilizedwith paraformaldehyde, by the same procedures
used for the production of RL platelets (7), to obtain SPIO-RL platelets.
Imaging phantoms and samples for magnetic characterization were
gelled in 1% w/v molecular-biology-grade agarose as an aqueous matrix
with diamagnetic properties similar to that of tissue, and with a mass of
nominally 0.2 g. For mass spectrometry and superconducting quantum
interference device (SQUID) magnetometry, positive control samples
were prepared with varying SPIO concentrations (200, 400, 600,
1000, and 2000 dilutions and control in citrated saline). Samples of
SPIO-RL platelets and negative control RL platelets were prepared in ci-
trated saline at 0.5  109 platelets/cm3 as determined by hemocytometry.
For details of MMOCT sample preparation, see Table S1 in the Supporting
Material, where the dilutions of SPIO for positive-control samples werechosen to match the Fe concentrations of the various SPIO-RL samples.
Mixtures of SPIO-RL and control RL platelets were employed to keep
the net concentration of platelets constant, thus controlling for any effects
due to platelets mechanically stiffening the matrix. Samples for MMOCT
were also combined with 0.5 mg/mL TiO2 micropowder (previously found
to have insignificant magnetization (20)) to provide optical scattering.Characterization of SPIO uptake by RL platelets
Inductively coupled plasma mass spectrometry (820-MS, Varian, Palo Alto,
CA) was employed to independently quantify iron uptake into platelets.
Samples ofvaryingSPIOconcentrationwereused for calibration.All samples
were digested overnight in trace-metal-grade nitric acid (5.67 mL/g sample)
and diluted 10 with deionized water. A calibration line (R2> 0.99) related
the expected SPIO Fe content (using the manufacturer’s value of 11.2 mg
Fe/mL) to the mass spectrometer reading. This was then used to compute
the Fe concentration in the platelet samples. Transmission electron micros-
copy of SPIO-RL platelets was performed as detailed elsewhere (25).
A colorimetric assay was used to quantify iron uptake into platelets as
follows. SPIOs exhibit a broad visible absorption band from the ultraviolet
up to 500 nm (brown), which contributes to the otherwise flat (white) scat-
tering spectrum of RL platelets. The total attenuation (scattering plus
absorption) measured at 370 nm (A370) is therefore a sum of both RL plate-
lets and SPIO content, whereas the ratio of attenuation values at 370 nm to
those at 600 nm (A370/A600) is a function of the SPIO content in the platelet
mixture (either added externally as a standard, or internalized in the plate-
lets). Suspensions of RL platelets at 0.2  109/cm3 were prepared, and
varying amounts of SPIO were added in amounts corresponding to the
range 0150 fg Fe/platelet. A standard curve of A370/A600 versus Fe
content/platelet was then used to quantify the Fe content of SPIO-RL plate-
lets based upon their attenuation spectra.Characterization of the magnetic properties
of SPIO-RL platelets
To determine the efficacy of SPIO-RL platelets as magnetomotive contrast
agents, we characterized their magnetic properties using SQUID magne-
tometry. (Note that Gaussian units or cgs emu are used in this article unless
stated otherwise. The two are the same for magnetic properties). The
magnetic properties of both SPIO-RL platelets and SPIO alone were
measured to probe any differences due to SPIO internalization by the plate-
lets. Diamagnetic plastic capsules (Quantum Design, San Diego, CA) were
loaded with ~100 mL of each sample. A 5T SQUID magnetometer (MPMS,
Quantum Design) was used to measure magnetization versus field hyster-
esis loops at 20C. Temperature-dependent field-cooled (FC) and zero-
field-cooled (ZFC) measurements at low fields between 50 and 2000 Oe
were also performed for SPIO-RL platelets and 200 SPIO samples to
probe the nature of their magnetic behavior. A typical ZFC measurement
involved first cooling the sample in nominal zero field from 300 to 5 K,
and then applying the field, with the measurement performed in the field
as the temperature was warmed to 360 K. The FC counterpart was per-
formed as the temperature was cooled from 360 K.
To accurately assess magnetic properties of dilute magnetic materials in
a biological medium, care must be taken to account for the diamagnetic
background of the medium (26). We addressed this by modeling the
field-dependent magnetizations of the superparamagnetic SPIO using
a Langevin function (first term in Eq. 1) and the weak diamagnetic or para-
magnetic contributions from the other constituent parts of the sample
(the second term in Eq. 1):
mðHÞ ¼ MsmS

coth

3cSH
Ms

 Ms
3cSH

þ cmmm þ cpnp þ chmhH:
(1)Biophysical Journal 99(7) 2374–2383
2376 Oldenburg et al.In this expression, m is the total magnetization; H is the applied magnetic
field; Ms is the saturation magnetization of the SPIO/mass of Fe; cs, cm,
and ch are the magnetic susceptibilities/mass of Fe in the SPIOs, the
medium (agarose and saline), and the plastic capsules, respectively; and
ms,mm, andmh are the masses corresponding to the c values. The respective
parameters for the platelets are cp, the magnetic susceptibility/number, and
np, the total number. These terms are introduced to account for the possible
contribution of paramagnetic iron in the platelets. For the SPIO-RL plate-
lets, ms is replaced by np, and thus,Ms and cs become the saturation magne-
tization and magnetic susceptibility/number of SPIO-RL platelets,
respectively. For each sample,mm andmhwere weighed,mswas determined
by the dilution factor of the SPIOs, and np was determined from the original
dilution by hemocytometry. Control samples were measured to indepen-
dently quantify cm, cp, and ch. Finally, cs and Ms were obtained for
SPIO-RL platelets and SPIOs by least-squares fitting of the magnetization
loops using Eq. 1.Model of magnetomotive properties of SPIO-RL
platelets
The measured magnetic properties were then used to create a computational
model of the magnetic gradient force induced in a blood clot loaded with
SPIO-RL platelets. We rewrite the magnetic gradient force equation in
the absence of external current as
F
V
¼ M ,VB>> MzBz;NpVBz
¼ Mz

Bz;Np

fmagnetBz; (2)
where force, F, per sample volume, V, is determined by the volume magne-
tization, M, and the gradient of the magnetic field, B. In our system, the
gradient terms are dominated by the axial (z) components Mz and Bz. Mz
is a function of Bz and platelet number density Np. In the absence of eddy
currents, an electromagnet can be described by a constant of proportional-
ity, fmagnet ¼ VBz=Bz, at a defined position relative to the magnet. This is
useful in that increasing the magnet supply current results in a proportional
increase in both Bz and VBz. To model our system, we take fmagnet ¼ 100/m
in the OCT imaging volume, because Bz changes by ~20% over the 2-mm
imaging depth. We then rewrite Eq. 1 as
Mz

Bz;Np
 ¼ mðBz=m0Þ
V
¼ MsNp

cothðxBzÞ  1
xBz

þ cmBz; (3)
where cm is now the volume magnetic susceptibility of the medium, taken
to be 8.6  107 emu/cm3 as an average value for human blood (21),
x ¼ 3cs=m0Ms, cs and Ms are the per-platelet values (see Table 2), and m0
is the permeability of free space. The net magnetizations are sufficiently
small to assume that Bz ¼ m0Hz.Porcine artery infusion experiments
To investigate their hemostatic properties, SPIO-RL platelets were perfused
with ex vivo porcine arteries with and without luminal wall damage.
Pigs from the Francis Owen Blood Research Laboratory were handled
according to protocols approved by the Institutional Animal Care and
Use Committee at the University of North Carolina at Chapel Hill.
A mesenteric artery was obtained from a 6-year-old normocholesterolemic
pig (serum cholesterol level 61 mg/dl) that had no gross evidence of athero-
sclerosis at necropsy. It is important to note that normocholesterolemic pigs
do not normally develop atherosclerosis, which only develops if the animal
is fed a high-fat diet to induce hypercholesterolemia (27). As such, controlBiophysical Journal 99(7) 2374–2383arteries obtained from the pig are undamaged and expected to elicit no
platelet response.
SPIO-RL platelet-containing blood was prepared by mixing one part
SPIO-RL platelets at 2  109/cm3 in citrated saline with nine parts porcine
blood collected in citrate anticoagulant. The resulting SPIO-RL platelet
concentration was 0.2  109/cm3, and the endogenous platelet concentra-
tion was 0.243  109/cm3. Immediately before infusion, the SPIO-RL
platelet-blood mixture was recalcified by adding 1M CaCl2 to achieve
a 10-mM calcium ion concentration. Two segments of the mesenteric artery,
each ~3 cm long, were flushed with citrated saline to remove endogenous
blood and dissected from surrounding connective tissues. One segment
was injured or deendothelialized using a 1-mm cytology brush (Wilson-
Cook Medical, Winston Salem, NC) by making five passes through the
vessel lumen. The other segment, used as a control, remained uninjured.
One end of each of the segments (damaged and control) was ligated with
a 5 Fr catheter, and 1.0 mL of the SPIO-RL platelet-blood mixture was
infused at a steady rate for 4 min. The vessels were subsequently flushed
with saline and cut into three segments, each ~1 cm long, for imaging.
A portion of a blood clot was removed from one section of the damaged
artery for imaging. As a control clot, citrated blood was drawn from another
normocholesterolemic pig and coagulated by recalcification as described
above.
At the volume flow rate in this experiment (4.2 mm3/s through vessels
3–5 mm in diameter) the maximum value for the shear rate is estimated
using the Poisseuille equation (28) to be 1.6/s, smaller than those typical
of arterial or venous blood (29). This shear rate may overestimate the actual
values, because the Poisseuille equation assumes a rigid cylindrical wall and
Newtonian blood, which typically results in over-estimation of the actual
shear rate (28). Therefore, we expect that the experimental shear rate value
is well below that required for shear-induced platelet activation (30).Magnetomotive OCT
A phase-resolved, spectral-domain OCT system was constructed to track
the induced magnetomotion of the SPIO-RL platelets (Fig. 1). The light
source consisted of a Ti:Sapphire laser (Griffin, Kapteyn-Murnane Labs,
Boulder, CO) producing ~125 nm of bandwidth centered near 810 nm,
corresponding to a coherence length of ~2 mm in tissue phantoms. The
source light was passed through a Faraday isolator and coupled into
a single-mode fiber for guidance into the OCT interferometer. A free-space
Michelson interferometer is comprised of a stationary reference arm con-
sisting of a variable attenuator and retroreflector, and a sample arm consist-
ing of x- and y-scanning galvanometer mirrors and a lens of 40 mm focal
length to provide 16 mm of transverse resolution with a confocal parameter
of ~0.5 mm. Nominally 10–14 mW of light power was delivered to the
sample, and backscattered light was collected and interfered with the refer-
ence light at the beamsplitter. The output light was then delivered by
a single-mode fiber to a spectrometer in which it was spectrally dispersed
by a 600-lines/mm grating in Littrow, and imaged by a biconvex lens of
200 mm focal length onto 2048 pixels of a line-scan camera operated at
1 kHz (Piranha 2, Dalsa, Waterloo, Ontario, Canada). The signal/noise ratio
of this system was determined to be >95 dB. The differential phase sensi-
tivity was determined to be 170 mrad by acquiring M-mode data from
a coverslip, which is equivalent to a displacement sensitivity of 11 nm.
Awater-jacketed solenoid coil was constructed to deliver predominantly
axially- (z-) directed magnetic field gradients into the 2 2 1.5-mm (x
y  z) OCT imaging volume for tissue-phantom imaging. For porcine
arteries, the OCT imaging volume in y was extended to 4 mm. The solenoid
is powered by a computer-controlled 250-W power supply, allowing for the
magnetic field and gradient to be modulated up to 0.15 T and 15 T/m,
respectively. The magnetic field was modulated with a square-root sinusoid
at 100 Hz to provide a purely sinusoidal gradient force. For phantom
imaging, data was collected into 2500  9  1024 pixels (x  y  z) by
acquiring nine sequential B-mode (x  z) images. For porcine artery
imaging, data was collected the same way, except that 4000 pixels were
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FIGURE 1 MMOCT system diagram (steering
mirrors not shown). FI, Faraday isolator; FC, fiber
coupler; SMF, single-mode fiber; PC, polarization
controller; BS, beamsplitter; GM, galvanometer
scanning mirrors; VA, variable attenuator; RR,
retroreflector; L, lens; EM, electromagnet; G,
grating; and C, camera.
OCT of Magnetic Platelets 2377obtained in x. Each B-mode image was processed according to a method
described previously (20) in which a bandpass filter is employed at
100 Hz and an additional phase filter is employed to reject diamagnetic
motion based upon the mechanical phase lag of the sample with respect
to the driving magnetic waveform. Image-averaged values of the MMOCT
signal were computed for each B-mode image and used to determine
a mean and standard deviation signal value for each sample.RESULTS
SPIO uptake by RL platelets
As shown in Fig. 2, SPIOs internalized by platelets occupy
a significant fraction of the platelet volume, organizing into
rodlike structures in the surface-connected open canalicular
system (31). Each structure can contain hundreds of indi-
vidual SPIOs (average core diameter ~5 nm). Table 1
summarizes the iron loading measured for SPIO-RL plate-
lets compared to RL platelets alone. Values obtained by
three different experimental techniques are in agreementFIGURE 2 Transmission electron micrographs of SPIO-RL platelets.
SPIOs display negative contrast in these transmission electron micrographs
and are shown to organize into rodlike structures (arrows).within experimental error. If we assume that the average
platelet volume is 10.6 fL (32), the fractional volume occu-
pied by the iron oxide cores of SPIOs in the RL platelets is
estimated to be 0.15%. The dextran and citrate coatings,
reported to be 5.69.1 and 0.250.53 mg/mL, respectively,
in the SPIO solution would be expected to occupy an addi-
tional fractional platelet volume of 0.350.58% assuming
a specific gravity of 1.Magnetic properties of SPIO-RL platelets
The magnetic properties of SPIO-RL platelets, RL-platelet
negative control, and SPIO positive control as measured
by SQUID magnetometry are summarized in Table 2.
We note that the cs and Ms of SPIO positive control is in
agreement with previous measurements of ferumoxides
(33). In addition, the magnetic susceptibilities of the gel
medium and plastic holder are determined to be (6.3 5
0.4) and (6.1 5 0.7)  107 emu/g, respectively. The
room-temperature field-dependent magnetization loops
exhibit no remanence and no hysteresis within experimental
uncertainty, as shown in Fig. S1 for a typical measurement
with a best fit using Eq. 1. Temperature-dependent measure-
ments (see Fig. S2) show FC and ZFC irreversibility (34).
The ZFC behavior exhibits a characteristic peak at 50 K,
and the onset of FC-ZFC irreversibility is ~100 K. The
blocking temperature is expected to be between the twoTABLE 1 Iron content of platelets determined by three
experimental methods
Iron content of platelets (fg Fe/platelet)
Colorimetric
assay
Mass
spectrometry
SQUID
magnetometry*
RL platelets — 3.05 0.4 <5
SPIO-RL platelets 43 5 11 48.35 0.6 455 7
*Magnetic forms of Fe only.
Biophysical Journal 99(7) 2374–2383
TABLE 2 Magnetic properties determined by SQUID magnetometry
Magnetic properties of platelets
cs, magnetic susceptibility
per mass
(emu/g Fe)
cs, magnetic susceptibility
per platelet
(emu/platelet)
Ms, saturation
magnetization/mass
(emu/g Fe)
Ms, saturation
magnetization per platelet
(emu/platelet)
RL platelets control - <91017 - (15 1)1013
SPIO-RL platelets (6.5 5 1.0)102 (3.25 0.5)1015 845 6 (4.05 0.6)1012
SPIO positive control (6.4 5 0.5)102 - 885 7 -
2378 Oldenburg et al.temperatures, which is consistent with the literature value
of ~60 K for ferumoxides (33).
The magnetic parameters cs and Ms for the SPIO-RL
platelets obtained by analyzing the SQUID data are per
platelet. The corresponding per-mass values were then
calculated using the iron loading of 48.3 fg Fe/platelet
measured by mass spectrometry, thus allowing for compar-
ison between the SPIOs and SPIO-RL platelets. As shown in
Table 2, the per-mass Fe values for magnetic susceptibility
and saturation magnetization are the same for SPIOs and
SPIO-RL platelets within experimental error.Magnetomotive properties of SPIO-RL platelets
The measured magnetic properties were then used to create
a computational model of the magnetic gradient force
induced in a blood clot loaded with SPIO-RL plateletsMagnetic Field (T)
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Biophysical Journal 99(7) 2374–2383according to Eqs. 2 and 3. As seen in Fig. S1, the diamagnetic
contribution of an aqueous medium is nonnegligible when
considering these forces. We find that the magnetic gradient
force on SPIO-RL platelets over the range of concentrations
used in our experiments is in the hundreds ofmN/cm3 (Fig. 3).
Positive values correspond to net paramagnetic forces from
the SPIOs, and negativevalues correspond to net diamagnetic
forces from the tissuemedium. It is important to point out that
to maximize MMOCT imaging contrast, the maximum para-
magnetic force at any given concentration is obtained at
a magnetic field significantly less than 1 T. For smaller
concentrations, the optimum magnetic field also becomes
smaller, and it becomes increasingly important not to employ
a large field to avoid a net negative force from the diamag-
netic medium. The minimum SPIO-RL platelet concentra-
tion below which no net positive force is obtained is
computed to be 0.27  109/cm3.s
it
y
(
1
/c
m
3
)
FIGURE 3 Magnetic-gradient force/volume as a function of
platelet density and magnetic field in a blood medium, accord-
ing to the computational model described in the text.
OCT of Magnetic Platelets 2379Magnetomotive OCT of SPIO-RL platelets
in tissue phantoms
We found that SPIO-RL platelets exhibited high contrast via
MMOCT in agarose scaffolds, in comparison to RL platelets
(Fig. S3). In standard OCT imaging, the highly scattering
TiO2 micropowder is contrasted, and no difference between
the RL platelets and SPIO-RL platelets can be observed
(P > 0.9, n ¼ 5, t-test, region of interest 0.1 mm2).
In MMOCT, specific contrast to the SPIO-RL platelets
becomes evident. As noted in previous work (20), autocor-
relation artifacts, which appear as vertical stripes immedi-
ately above the surface of the sample in the OCT images,
are not observed in the MMOCT images. This is because
magnetomotion is detected as relative motion between the
sample and reference arms of the interferometer, whereas
the autocorrelation signal is unchanged.
The concentration-dependent MMOCT signal was found
for SPIOs and SPIO-RL platelets (Fig. 4), where the signal,
as defined previously (20), is related to the amplitude of the
sinusoidal sample displacement at the driving magnetic
modulation frequency. This displacement amplitude is
a function of both the SPIO concentration and the tissue
elasticity. For concentrations at or above 1.5  109 plate-
lets/cm3, the MMOCT signal is significantly above theFIGURE 4 Image-averaged MMOCT signal (upper) and mechanical
phase lag (lower) are plotted versus iron concentration for free SPIO
positive control samples and SPIO-RL platelets. The corresponding platelet
concentration is displayed on the top axis. Net paramagnetic and diamag-
netic forces exhibit in-phase and out-of-phase motion, respectively, with
the magnetic driving waveform.background (P < 0.0001, n ¼ 9, t-test). For both SPIOs
and SPIO-RL platelets, a clear transition from net diamag-
netic motion to net paramagnetc motion over increasing
concentration is observed. Although the filter partially
suppresses the diamagnetic signal, a small negative bias
remains at zero concentration (nominally 0.5 5 0.2 dB).
Because diamagnetic motion is out of phase with the
magnetic driving waveform, the phase lag at zero concentra-
tion is near 5p. As the concentration is increased, the net
force balance shifts to paramagnetic (in-phase) motion
arising from the SPIOs. Thus, as the MMOCT signal
increases, the phase lag simultaneously nears zero. Because
there is a high magnetic field gradient in our system, a signif-
icant source of error arises from differences in the magnetic
field at the sample due to its positioning (~30% change in
force over 1 mm in depth), which is partially mitigated by
aligning the sample surface to the same position within
the OCT image. This may account for the apparent differ-
ence in the concentration threshold above which MMOCT
contrast is obtained for the SPIOs and the SPIO-RL
platelets. Also, saturation of the MMOCT signal occurs
above ~3 dB. This occurs because the velocity of the
magnetomotion becomes too large and causes a phase shift
of >p of the optical phase measured in successive samples
by OCT, resulting in an underestimate of the magnetomo-
tion when performing phase unwrapping. This is easily
mitigated in practice by reducing the magnetic field strength
to an appropriate value, or by increasing the camera
sampling rate.Imaging and hemostasis of SPIO-RL platelets
in porcine arteries
To investigate the ability of SPIO-RL platelets to adhere to
sites of vascular damage, they were perfused with ex vivo
porcine arteries both with and without luminal wall damage.
It was observed that a nonocclusive hemostatic plug (blood
clot) had formed in the damaged artery after the 4-min infu-
sion period, whereas the control exhibited no clotting.
Subsequently, MMOCT of damaged and control arteries
was performed (Fig. 5 and Fig. S4). Arteries were imaged
both uncut from the exterior, and cut longitudinally with
the luminal wall exposed. Both cut and uncut control
arteries exhibited MMOCT signals similar to control phan-
toms (Table 3). In the damaged artery, one cut segment
exhibited signal similar to that of control, whereas a second
segment exhibited MMOCT signals significantly larger than
control signals both uncut and cut. It was noted that the first
segment had displayed little macroscopic evidence of
clotting (red color from trapped erythrocytes) compared to
the second segment, which exhibited redness and large
MMOCT signals. A portion of the clot from the damaged
artery was also removed and found to have a large MMOCT
signal and near-zero phase lag similar to diamagnetic
samples, which was in contrast to the control clot. TheseBiophysical Journal 99(7) 2374–2383
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FIGURE 5 Sample B-mode images
of ex vivo porcine arteries after expo-
sure to SPIO-RL platelets in a flow
chamber. (A) OCT of control artery.
(B) OCT of damaged artery. (C)
MMOCT of control artery. (D)
MMOCT of damaged artery. These are
longitudinally cut arteries with the
luminal wall facing upward. Scale bar:
0.5 mm.
2380 Oldenburg et al.ex vivo studies, which mimic the vascular injuries that might
be expected in some types of traumatic injury or vascular
disorders, demonstrate that SPIO-RL platelets retain the
native platelet functions that mediate localization to sites
of endothelial damage.DISCUSSION
SPIO uptake by RL platelets
The observation that platelets take up SPIO is not surprising
in light of previous reports, where platelets have been noted
to take up carbon (35), latex (36), cationic ferritin (37),
colloidal gold (31), model viruses (38) and bacteria (39).
Bacteria are occluded in the surface-connected open cana-
licular system (31,40), a system of membranes formed
from invaginations of and spatially contiguous with the
surface membrane. These observations suggest that platelets
play a more important innate immune (host defense) role
than is widely appreciated, and that SPIOs are accumulated
through this set of immunity mechanisms.
Excellent agreement between three different experi-
mental techniques (colorimetric, mass spectrometry, and
SQUID magnetometry) lends a high degree of confidence
to our measurement of the iron content of SPIO-RL platelets
(4348 fg/platelet). We found that although there is a signif-TABLE 3 Summary of MMOCT signals from ex vivo experiments in
Magnetomotive OCT of porcine arteries and clots
MMOCT signal (dB)
Control artery segment 1 Uncut 0.445 0.10
Control artery segment 2 Cut 0.125 0.15
Damaged artery segment 1 Cut 0.305 0.14
Damaged artery segment 2 Uncut 3.255 0.93
Damaged artery segment 2 Cut 3.695 0.55
Clot from normal blood 0.585 0.69
Clot from damaged artery 2.075 0.61
Biophysical Journal 99(7) 2374–2383icant fractional volume of iron oxide in the RL platelets
(0.15%), the volume occupied by the SPIO coating mole-
cules (dextran and citrate) is approximately three times
larger. This suggests that reducing the coating material
while maintaining the integrity of the colloidal dispersion
may significantly increase the SPIO loading into RL plate-
lets. It has also been suggested that dextran is undesirable
as a stabilizing ligand, as it becomes easily dissociated in
solution unless cross-linked (41).Magnetic properties of SPIO-RL platelets
The dispersed SPIO and SPIO in RL platelets exhibit super-
paramagnetism. The behaviors of the two are nearly identical,
including the superparamagnetic moment and the tempera-
ture dependence, despite the fact that the SPIOs inside RL
platelets appear to be tightly packed (Fig. 2). This result indi-
cates that the magnetic coupling between SPIO nanoparticles
is weak. This is consistent with the results of previous work,
where SPIOs of similar core size were shown to interact only
weakly for interparticle spacings of ~>7 nm (42), which is
small compared to the expected spacing due to the coating
molecules on our SPIO (~15 nm). However, these results do
not rule out the role played by magnetic interactions in the
formation of the rodlike structures in the RL platelets. Further
study is needed to elucidate this. It is interesting to note that toporcine arteries
MMOCT phase lag (rad) P-value Number of images
3.135 0.21 9
1.845 1.04 9
2.905 0.38 - 18
0.625 0.06 <106 9
0.415 0.05 <106 7
2.405 1.30 9
0.725 0.70 0.00018 9
OCT of Magnetic Platelets 2381our knowledge, there have been no previous reports of
rod-shaped accumulation of magnetic or nonmagnetic
particles in platelets. We note that during incubation of RL
plateletswith SPIOs, no externalmagnetic fieldswere present
except that of the earth.
Amagnetic-gradient-forcemodelwas employed to predict
the response of a thrombus labeled with SPIO-RL platelets
using the measured magnetic properties. According to the
model, the magnetic-gradient forces range from tens to
hundreds ofmN/cm3, depending on the platelet concentration
and applied field.We chose a range of platelet concentrations
up to 3  109/cm3, which corresponds to ~0.9% volume
loading of platelets. In comparison, a typical thrombus has
been found to contain between 3570% area (or, by
extrapolation, 2060% volume) of platelets (43). We expect
that only a fraction of the platelets in a thrombus will be
composed of SPIO-RL platelets during a typical infusion
application, and therefore, 3  109/cm3 is a reasonable
estimate for the upper limit of platelet concentrations. It is
important to note that this model allows us to predict the
optimal applied magnetic field by which to maximize
the net paramagnetic force. This optimum field is signifi-
cantly less than 1T for the relevant range of
platelet concentrations, because the nonnegligible tissue
magnetization continues to grow larger for increasing fields
after the SPIOs have reached saturation (~0.2 T). This relaxes
the requirements on the electromagnet for the MMOCT
system, permitting the use of a relatively small, water-jack-
eted solenoid coil.Magnetomotive OCT of SPIO-RL platelets
In tissue phantoms, we observed significant MMOCT
contrast of SPIO-RL platelets in 1% w/v agarose at concen-
trations R1.5  109/cm3. Comparing this with predictions
from our force model by assuming that the 1% agarose
has an elastic modulus of 50 kPa (44) and a thickness
of ~5 mm, we estimate, using Hooke’s law, that a tissue
displacement of 23 nm is obtained at this concentration.
This is consistent with our OCT-system differential phase
sensitivity of 11 nm, and it may explain why lower concen-
trations, although theoretically providing paramagnetic
motion, were not contrasted due to displacements below
our sensitivity. As a point of comparison, arteries are known
to have an elastic modulus of 50115 kPa (45), and abdom-
inal aortic thrombi measured under tension have elastic
moduli ranging from 42 to 540 kPa (46). In future work, it
may be possible to significantly improve the phase sensi-
tivity of the MMOCT system by the use of a common-
path interferometer; such OCT systems have demonstrated
sensitivities of <1 nm (47).
In ex vivo porcine arteries, we found that MMOCT
signals of damaged artery were significantly larger than
control when arteries were infused with SPIO-RL platelets.
Because control clots untreated with SPIO-RL plateletsshowed no significant MMOCT signal, we conclude that
the activity of the SPIO-RL platelets caused the specific
MMOCT contrast to the damaged arteries. These studies
demonstrate that, as is the case with the native platelets,
SPIO-RL platelets have the ability to adhere to sites of
vascular injury and incorporate into blood clots. Futher-
more, SPIO-RL platelets did not adhere in a measurable
amount to uninjured endothelium, which suggests that
they are not rendered prothrombotic and confirms the
activatable nature of SPIO-RL platelet adhesion. In
a previous study, the hemostatic function of RL platelets
was shown to be mediated by primary hemostatic mecha-
nisms working in concert with the activatable ability of
the cell membrane to catalyze coagulation cascade turnover
(11), and future studies are needed to compare these proper-
ties with that of the SPIO-RL platelets. It is important to
point out that the activatable SPIO-RL platelet adhesion
was demonstrated in the presence of endogenous platelets,
as would be the case in most potential indications for this
imaging therapeutic. As such, these ex vivo results are
highly promising for the feasibility of employing SPIO-
RL platelets to contrast sites of vascular damage in vivo.CONCLUSIONS
By developing a force model, we predict that contrast of
SPIO-RL platelets will be possible using MMOCT with
a threshold concentration of 0.27 109 platelets/cm3, where
the diamagnetic and paramagnetic forces are exactly
balanced. We found that around five times this concentration
was needed in practice to detect SPIO-RL platelets using
MMOCT, which corresponds to one SPIO-RL platelet out
of ~80 native platelets in a typical thrombus. We also found
that ex vivo porcine arteries exhibited specific MMOCT
contrast when damaged and then exposed to SPIO-RL plate-
lets. Although these results are encouraging with respect to
potential applications in biomedical imaging of infusible
SPIO-RL platelets, further study in vivo is needed to measure
the efficiency with which SPIO-RL platelets label thrombi or
other sites of arterial damage during a typical infusion appli-
cation. Future improvement of the iron uptake efficiency of
the platelets, perhaps by reducing the amount of the coating
molecules currently occupying a large volume of the total
SPIO footprint, may considerably improve the contrast
of SPIO-RL platelets. We have demonstrated ex vivo that
the SPIO-RL platelets specifically label sites of vascular
damage, which may enable new technologies. This may in-
clude the use of intravascular OCT imaging for the detection
of thrombosis, and exterior OCT imaging for monitoring the
efficacy of SPIO-RL platelets during treatment for trauma.SUPPORTING MATERIAL
One table and four figures are available at http://www.biophysj.org/
biophysj/supplemental/S0006-3495(10)00973-2.Biophysical Journal 99(7) 2374–2383
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